Clinical Trial Update: Positron Emission Tomography (PET) Study With (11C) Flumazenil to Determine Central GABAA Receptor Occupancy of AZD6280 [Phase 1]

View source ↗

Summary

Phase 1 PET study update evaluating central GABAA receptor occupancy of AZD6280 using (11C) flumazenil in participants with anxiety.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anxiety Disorders

Drugs mentioned

• AZD6280 (AZD6280)

Snippet

Sponsor: AstraZeneca | Conditions: Anxiety | Phase 1 | Status: COMPLETED